Science Explorer Back to mapMap
Discussion
Company · Heidelberg · Germany

Affimed Therapeutics (Germany)

affimed.comROR OpenAlex
Research works
101
▼ 4% vs 2018-21
Citations
2k
19.7 per fractional work
Top-10% rate
19.2%
all institutions 10.0%
Open access
27%
world 40%
International
29%
world 18%
Affimed Therapeutics (Germany)

Not ranked overall: Affimed Therapeutics (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Affimed Therapeutics (Germany) work in?

In all years, 62% of research at Affimed Therapeutics (Germany) is in Health Sciences, 36% in Life Sciences. Its largest fields are Medicine (62%), Immunology and Microbiology (19%), Biochemistry, Genetics and Molecular Biology (16%). It does 2.5× the world's share of Health Sciences.

Health Sciences: 62 fractional works · 62.0% of its workMedicine: 62 fractional works · 61.7% of its workRadiology, Nuclear Medicine and Imaging: 26 fractional works · 25.8% of its workOncology: 24 fractional works · 24.0% of its workPathology and Forensic Medicine: 4 fractional works · 3.8% of its workHematology: 3 fractional works · 2.6% of its workImmunology and Allergy: 2 fractional works · 1.6% of its workGenetics: 1 fractional works · 1.3% of its workEpidemiology: 1 fractional works · 1.1% of its workPhysiology: 0 fractional works · 0.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.3% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.2% of its workDermatology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.4% of its workNursing: 0 fractional works · 0.2% of its workNutrition and Dietetics: 0 fractional works · 0.2% of its workHealth Professions: 0 fractional works · 0.1% of its workLife Sciences: 36 fractional works · 36.1% of its workImmunology and Microbiology: 19 fractional works · 19.3% of its workImmunology: 19 fractional works · 19.3% of its workBiochemistry, Genetics and Molecular Biology: 16 fractional works · 15.5% of its workMolecular Biology: 12 fractional works · 12.3% of its workBiotechnology: 2 fractional works · 1.9% of its workCancer Research: 0 fractional works · 0.5% of its workCell Biology: 0 fractional works · 0.3% of its workGenetics: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workNeuroscience: 1 fractional works · 0.8% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.3% of its workSmaller subfields together: 1 fractional works · 0.5% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.3% of its workAgricultural and Biological Sciences: 0 fractional works · 0.1% of its workPhysical Sciences: 2 fractional works · 1.9% of its workEngineering: 1 fractional works · 0.8% of its workBiomedical Engineering: 1 fractional works · 0.8% of its workMaterials Science: 1 fractional works · 0.7% of its workBiomaterials: 1 fractional works · 0.7% of its workChemistry: 0 fractional works · 0.4% of its workMathematics: 0 fractional works · 0.0% of its workSocial Sciences: 0 fractional works · 0.1% of its workBusiness, Management and Accounting: 0 fractional works · 0.0% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.0% of its workALL ITS WORKAffimedTherapeutics…101fractional works, all years
Life Sciences36%Physical Sciences2%Health Sciences62%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 14 fields, with their numbers
    1. Medicine6261.7%
    2. Nursing00.2%
    3. Health Professions00.1%
    1. Immunology and Microbiology1919.3%
    2. Biochemistry, Genetics and Molecular Biology1615.5%
    3. Neuroscience10.8%
    4. Pharmacology, Toxicology and Pharmaceutics00.3%
    5. Agricultural and Biological Sciences00.1%
    1. Engineering10.8%
    2. Materials Science10.7%
    3. Chemistry00.4%
    4. Mathematics00.0%
    1. Business, Management and Accounting00.0%
    2. Economics, Econometrics and Finance00.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.97× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 32.25× its world share, 6 worksImmunology and Micro…Neuroscience: 0.94× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 1.28× its world share, 0 worksPharmacology, Toxico…Engineering: 0.03× its world share, 0 worksEngineeringMaterials Science: 0.38× its world share, 0 worksMaterials ScienceMathematics: 0.16× its world share, 0 worksMathematicsHealth Professions: 0.13× its world share, 0 worksHealth ProfessionsMedicine: 2.71× its world share, 9 worksMedicineNursing: 0.48× its world share, 0 worksNursingBusiness, Management and Accounting: 0.05× its world share, 0 worksBusiness, Management…Economics, Econometrics and Finance: 0.09× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 32.2×. Every wedge is a field page.

All 12 fields, with their numbers
  1. Immunology and Microbiology32.25×6 works
  2. Medicine2.71×9 works
  3. Biochemistry, Genetics and Molecular Biology1.97×2 works
  4. Pharmacology, Toxicology and Pharmaceutics1.28×0 works
  5. Neuroscience0.94×0 works
  6. Nursing0.48×0 works
  7. Materials Science0.38×0 works
  8. Mathematics0.16×0 works
  9. Health Professions0.13×0 works
  10. Economics, Econometrics and Finance0.09×0 works
  11. Business, Management and Accounting0.05×0 works
  12. Engineering0.03×0 works

Who are the top researchers at Affimed Therapeutics (Germany)?

Ranked on the quality score, Jens H. W. Pahl, Gabriele Hintzen and Eugene A. Zhukovsky lead among researchers whose main affiliation is Affimed Therapeutics (Germany).

  1. 1 Jens H. W. Pahl Germany · #205,759 worldwide 1.4k citations · 43 works
  2. 2 Gabriele Hintzen Germany · #352,721 worldwide 3.1k citations · 51 works
  3. 3 Eugene A. Zhukovsky Germany · #411,738 worldwide 2.9k citations · 75 works
  4. 4 Fionnuala McAleese Germany · #414,765 worldwide 3.1k citations · 26 works
  5. 5 Uwe Reusch Germany · #762,498 worldwide 2.9k citations · 118 works
  6. 6 Michael Tesar Germany · #920,426 worldwide 1.7k citations · 45 works
  7. 7 Erich Rajkovic Germany · #959,527 worldwide 519 citations · 58 works
  8. 8 Stefan H.J. Knackmuss Germany · #978,364 worldwide 1.8k citations · 70 works
  9. 9 Ivica Fucek Germany · #1,033,774 worldwide 747 citations · 49 works
  10. 10 Kristina Ellwanger Germany · #1,037,544 worldwide 1.3k citations · 56 works
All ranked researchers at Affimed Therapeutics (Germany)

What are the most cited papers from Affimed Therapeutics (Germany)?

The most cited paper from Affimed Therapeutics (Germany) is "Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma" (Christopher James Gibson et al., 2017), with 483 citations. Next come "A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma" (336) and "A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells" (162).

Most cited papers
#PaperReleasedCitations
1 Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma Christopher James Gibson et al. · Journal of Clinical Oncology Open access 23 Feb 2017 483
2 A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Achim Rothe, Stephanie Sasse, Max S. Topp et al. · Blood Open access 17 Apr 2015 336
3 A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells Uwe Reusch, Carmen Burkhardt, Ivica Fucek et al. · mAbs Open access 25 Mar 2014 162
4 Of mice and men: hybridoma and recombinant antibodies Melvyn Little, Sergey M. Kipriyanov, Fabrice Le Gall et al. · Immunology Today Aug 2000 157
5 Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies Lucila Nassif Kerbauy et al. · Clinical Cancer Research Open access 13 May 2021 154
All 62 most cited papers, with filters and sorting

Which keywords describe research at Affimed Therapeutics (Germany)?

By fractional works in all years, weighted toward what it does more of than the world: Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors, Cancer Immunotherapy, Lymphoma and Immunotherapy.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Glycosylation32▲ 146×3 topics
  2. Monoclonal Antibodies27▲ 187×3 topics
  3. Therapeutic Antibodies26▲ 200×2 topics
  4. Antibody Engineering24▲ 243×1 topic
  5. Fc Receptors24▲ 243×1 topic
  6. Cancer Immunotherapy23▲ 166×3 topics
  7. Lymphoma22▲ 149×3 topics
  8. Immunotherapy20▲ 30×5 topics
  9. Tumor Regression20▲ 223×2 topics
  10. CAR T Cells18▲ 423×1 topic
  11. Chimeric Antigen Receptor18▲ 423×1 topic
  12. Leukemia18▲ 281×2 topics
  13. Cancer10▲ 6.9×5 topics
  14. NK Cell Recognition8▲ 82×1 topic
  15. Natural Killer Cells8▲ 82×1 topic
  16. Immune System7▲ 21×2 topics
  17. Glycans7▲ 81×1 topic
  18. Mucins7▲ 81×1 topic
  19. PET Imaging6▲ 27×3 topics
  20. Rituximab5▲ 31×2 topics
  21. Innate Immunity4▲ 12×3 topics
  22. Immunity4▲ 12×2 topics
  23. Antigen Presentation4▲ 37×1 topic
  24. Autoimmunity4▲ 18×2 topics
  25. Dendritic Cells4▲ 33×1 topic
  26. Classification4▲ 10×1 topic
  27. Molecular Profiling4▲ 31×1 topic
  28. Angiogenesis4▲ 8.4×5 topics
  29. Tumor Microenvironment4▲ 9.9×5 topics
  30. Biopharmaceuticals3▲ 50×3 topics
  31. Monoclonal Antibody3▲ 49×2 topics
  32. Prognostic Factors3▲ 6.1×5 topics
  33. Foxp33▲ 35×1 topic
  34. Immunogenicity3▲ 49×2 topics
  35. TGF-ß3▲ 15×1 topic
  36. Immune Checkpoint Blockade2▲ 43×1 topic
  37. PD-1 and PD-L12▲ 43×1 topic
  38. Immune Regulation2▲ 17×2 topics
  39. Recombinant Proteins2▲ 43×2 topics
  40. Protein Aggregation2▲ 26×2 topics

Which research topics does Affimed Therapeutics (Germany) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Immune Cell Function and Interaction, Monoclonal and Polyclonal Antibodies Research and T-cell and B-cell Immunology.

CAR-T cell therapy resea…4CAR-T cell therapy research: 4 fractional worksImmune Cell Function and…3Immune Cell Function and Interaction: 3 fractional worksMonoclonal and Polyclonal Antibodies Research: 2 fractional worksT-cell and B-cell Immunology: 1 fractional worksImmunotherapy and Immune…1Immunotherapy and Immune Responses: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksLymphoma Diagnosis and Treatment: 0 fractional worksGlycosylation and Glycoproteins Research: 0 fractional worksPhagocytosis and Immune Regulation: 0 fractional worksProtein purification and stability: 0 fractional works
OncologyImmunologyRadiology, Nuclear Medicine and ImagingPathology and Forensic Medicine1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 4 works
  2. 2 Immune Cell Function and Interaction Immunology 3 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
  4. 4 T-cell and B-cell Immunology Immunology 1 works
  5. 5 Immunotherapy and Immune Responses Immunology 1 works
  6. 6 Cancer Immunotherapy and Biomarkers Oncology 1 works
  7. 7 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
  8. 8 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  9. 9 Phagocytosis and Immune Regulation Immunology 0 works
  10. 10 Protein purification and stability Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available27.3%not open72.7%

World: 40% of research is openly available.

with international co-authors29.3%domestic only70.7%

World: 18% is written across borders.

How has Affimed Therapeutics (Germany)'s research output changed?

Output in 2022-2025 was 4% lower than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Affimed Therapeutics (Germany) as a percentage of every work published that year, 0.000016% in 2024.

still counting0.00020%0.00040%Affimed Therapeutics (Germany)0.000071% in 202520102020

Fractional works of Affimed Therapeutics (Germany) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Heidelberg

All research institutions in Heidelberg

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Affimed Therapeutics (Germany). Posts are plain text and can be reported.